Defand Therapeutics is a startup biotech with a patented target-oriented, cell-survival based, phenotypical high throughput screening platform, DEFUSE, which trail-blazes in searching of molecular glue degrader hits that can be developed into new therapeutics in oncology, immunology, neurodegeneration, metabolism, infection areas.